SCHEMBL5377740

SCHEMBL5377740

CCCc1nn(C)c2c(-c3ccc(C)cc3)nc(-c3ccc(F)cc3)nc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
HTT P42858 1/20 0.40
KDM4C Q9H3R0 1/20 0.39
ALDH1A1 P00352 2/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
HPGD P15428 1/20 0.36
PDE1A P54750 1/20 0.36
PDE1B Q01064 1/20 0.36
PDE1C Q14123 1/20 0.36
MTOR P42345 1/20 0.36
TDP2 O95551 1/20 0.35
SIRT1 Q96EB6 1/20 0.35
SRC P12931 1/20 0.35
BRAF P15056 1/20 0.35
KDR P35968 1/20 0.35
GAA P10253 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5410928 0.91 PDE5A (0.51) PDE5ASMN1; SMN2RAB9ANPC1HTT
SCHEMBL5360622 0.88 MAPK13 (0.39) PDE5ASMN1; SMN2RAB9ANPC1HTT
SCHEMBL5361630 0.86 PTGS2 (0.43)
SCHEMBL6103493 0.85 PDE5A (0.39) PDE5ASMN1; SMN2RAB9ANPC1HTT
SCHEMBL5371349 0.84 MTOR (0.40) PDE5ASMN1; SMN2RAB9ANPC1HTT
SCHEMBL5361647 0.82 PDE5A (0.43) PDE5ASMN1; SMN2RAB9ANPC1HTT
SCHEMBL5355823 0.82 PDE5A (0.41) PDE5ASMN1; SMN2RAB9ANPC1HTT
SCHEMBL5369656 0.82 PDE5A (0.38) PDE5ASMN1; SMN2RAB9ANPC1HTT
SCHEMBL5333399 0.79 PDE5A (0.41) PDE5ASMN1; SMN2RAB9ANPC1HTT
Hydrochloric Acid SCHEMBL5372075 0.78 PDE5A (0.40) PDE5ASMN1; SMN2RAB9ANPC1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814885-A2 NOVEL BICYCLIC HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM Reddy US Therapeutics, Inc. (US) 2007-08-08 EP claimed
WO-2006073610-A2 NOVEL BICYCLIC HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS, INC. (US) 2006-07-13 WO claimed
US-20060128729-A1 Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-06-15 US claimed
US-20060128729-A1 Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128729-A1 Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them HPSE, ENGASE, UGCG PDE5A 3544/4885SMN1; SMN2 3629/4885RAB9A 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.